Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study)

Effects of behavioural activation on psychological distress among people with cancer: A systematic review and meta-analysis

BACKGROUND

Cancer is a life-threatening disease that can have a significant impact on patients' psychological well-being. Behavioural activation is an emerging psychological therapy that has been suggested effective in improving depression and anxiety. However, no review has yet summarised its effects on psychological distress among people with cancer.

OBJECTIVE

To identify studies of behavioural activation designed for people with cancer and examine the effects on psychological distress, including depression and anxiety.

DESIGN

Systematic review and meta-analysis.

METHODS

A systematic search of PubMed/MEDLINE, CINAHL, EMBASE, PsycINFO, and the Cochrane Library was performed from the inception to 6 April 2024. Randomised controlled trials reporting on the effects of behavioural activation on psychological distress among cancer patients were included. Two authors independently screened the eligible studies, assessed the quality of studies, and extracted data. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2). The meta-analysis was performed by Review Manager 5.4, and narrative synthesis was employed when the meta-analysis was inappropriate. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used to assess the certainty of the evidence.

RESULTS

A total of nine studies were included in this systematic review, with 1811 participants. The pooled analysis showed that behavioural activation could improve depression (SMD = -0.24, 95 % CI -0.44 - -0.03, p = 0.020; moderate quality of evidence), and anxiety (SMD = -0.56, 95 % CI -1.01 - -0.10, p = 0.020; low quality of evidence) among people with cancer. The effects were robust in sensitivity analysis and yielded consistent results in studies that were not pooled due to insufficient data. Subgroup analyses suggested that face-to-face and group administration were more effective, whereas the effects of different dosages were uncertain. Besides, the effects of behavioural activation at different follow-up periods were not identified There was no consensus on the optimal components of intervention.

CONCLUSIONS

The evidence for behavioural activation as an effective treatment of psychological distress among people with cancer is promising. However, it should be noted that the quality of evidence was moderate and low, thus emphasising the need for caution when applying these findings. In order to explore which components may be most effective in improving psychological outcomes, more rigorous study designs and more detailed descriptions of interventions are necessary.

REGISTRATION

The protocol was registered on PROSPERO (Registration number: CRD42024533171).

Are digital psychological interventions for psychological distress and quality of life in cancer patients effective? A systematic review and network meta-analysis

BACKGROUND

Many cancer patients experience psychological distress and/or poor quality of life during or after their cancer treatment, yet they face multiple barriers to accessing psychological support. Digital psychological interventions represent a promising approach for addressing these barriers, however their comparative effectiveness remains uncertain.

METHODS

Nine databases were searched for randomized controlled trials (RCTs) from inception to July 2024. The primary outcomes were psychological distress and quality of life, and the secondary outcomes were measures of depression, anxiety, insomnia, fatigue, and fear of cancer recurrence in this study.

RESULTS

One hundred and thirty-six RCTs with 23,154 participants were identified. Of these interventions, three types-digitally-delivered cognitive behavioral therapy (CBT), health education, and virtual reality therapy (VRT)-demonstrated significant reductions in psychological distress compared to non-active controls. Digital CBT, narrative interventions, and VRT significantly improved quality of life compared to non-active controls. For depression, both digital CBT and VRT were superior to the non-active control group. Regarding anxiety, CBT, psychoeducation, and VRT outperformed the non-active control group. In terms of fatigue, CBT, psychoeducation, VRT, and multi-component interventions all showed enhanced efficacy compared to the non-active control group. However, only CBT exhibited significantly superior effectiveness in alleviating insomnia compared to non-active controls. Similarly, only mindfulness-based interventions significantly reduced fear of cancer recurrence compared to the non-active control condition.

CONCLUSIONS

Our results suggest that digital CBT and VRT are highly promising options for reducing psychological distress and enhancing the quality of life among cancer patients; further high-quality randomized controlled trials involving diverse populations are essential to validate these findings.

Smartphone-based distress screening, information provision, and psychotherapy for reducing psychological distress among AYA cancer survivors: protocol for a fully decentralized multicenter randomized controlled clinical trial

Fear of cancer recurrence (FCR) is a common and distressing condition among adolescents and young adults (AYAs). This study aims to investigate the efficacy of digital interventions, including distress screening-based information provision and smartphone problem-solving therapy, on common psychological distress, especially FCR, in AYA patients with cancer. Participants will be 224 AYA outpatients with cancer aged 15-39 years who will be randomly assigned to either an 8-week smartphone-based intervention or a waitlist control group. This intervention includes smartphone-based distress screening, information provision, and psychotherapy (problem-solving therapy). The primary endpoint will be the Fear of Cancer Recurrence Inventory-Short Form score at week 8. This study will be conducted as a fully decentralized, randomized, and multicenter trial. The study protocol was approved by the Institutional Review Board of Nagoya City University on 19 April 2024 (ID: 46-23-0005). Trial registration: UMIN-CTR: UMIN000054583.

Research on the soothing Liver - Qi stagnation method in the treatment of postoperative papillary thyroid carcinoma patients' concomitant depression: A randomized controlled clinical trial

BACKGROUND

Postoperative papillary thyroid carcinoma (P-PTC) patients often grapple with depression fueled by the looming threat of recurrence. While the Liver-Qi stagnation method is frequently employed for depression management, a notable scarcity of clinical trials exists regarding its application in patients with P-PTC and concurrent depression. This study presents a randomized controlled clinical trial, aiming to establish the efficacy of the Liver-Qi stagnation method in alleviating depression in patients with P-PTC.

METHODS

In this randomized controlled clinical trial, P-PTC patients diagnosed with concomitant depression were systematically enrolled. Subjects were randomly assigned to either the control or test group, both receiving standard treatment comprising Levothyroxine sodium tablets and decoction of benefiting Qi and nourishing Yin. Additionally, the test group received supplementation with bupleuri radix-paeoniae alba radix (CH-BS) alongside the baseline therapy. The intervention spanned 12 weeks. Pre- and post-treatment evaluations were conducted using the Hamilton Depression Scale (HAMD), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and Traditional Chinese Medicine (TCM) syndrome score scale. Concurrently, blood inflammatory factors and serum 5-hydroxytryptamine (5-HT) levels were measured to comprehensively assess treatment outcomes.

RESULTS

During the 12-week intervention, the test group demonstrated a significant reduction in HAMD scores compared to the control group (P < .05). Moreover, post-treatment serum 5-HT levels were significantly elevated in the test group compared to the control group (P < .05). Findings gleaned from the EORTC QLQ - C30 revealed a noteworthy improvement in social function and overall quality of life scores within both groups post-treatment in comparison to baseline (P < .05). Concurrently, post-treatment scores for fatigue and insomnia symptoms witnessed a significant decrease compared to baseline (P < .05). Notably, the test group exhibited superior scores in the emotional domain in contrast to the control group (P < .05). Both groups exhibited a substantial decrease in TCM syndrome scores from baseline (P < .05). Noteworthy increases were found in IFN-γ < 2.44 rate (62.86%) and IL-6 < 2.44 rate (74.29%) in the test group compared to pretreatment levels (P < .05).

CONCLUSION

The soothing Liver-Qi stagnation method induces a rise in serum 5-HT levels, reducing depression-related inflammatory factors, culminating in the alleviation of depression for P-PTC.